Rosetta Genomics, Ltd. (Rosetta Genomics) has signed a distribution agreement with Teva Pharmaceutical Industries Ltd (Teva Pharmaceutical). As per the terms of the agreement Teva will offer Rosetta Genomics' miRview tests in Israel and Turkey. The terms of the distribution agreement were not disclosed.

“This is yet another important step in Rosetta Genomics’ commercialization efforts,” noted Ronen Tamir, Chief Commercialization Officer at Rosetta Genomics. “As Israel provided its citizens with health insurance under the National Health Law, it represents a very attractive market for us. Teva has gained unsurpassed experience in marketing and obtaining reimbursement for complex molecular tests in Israel, and we are very excited to be partnering with them on these important tests. We are also excited to have Teva distribute our tests in Turkey, a country with significant market potential.”

The following tests will be distributed by Teva Pharmaceuticals:

miRview mets – This test can accurately identify the primary tumor site in patients presenting with metastatic cancer, as well in patients whose tumor has not been identified, and consequently been labeled Cancer of Unknown Primary (CUP).

miRview squamous – Using a single microRNA, miRview(TM) squamous differentiates squamous from non-squamous, non-small cell lung cancer (NSCLC) patients.

miRview meso – The test leverages microRNA’s high specificity as biomarkers, to differentiate mesothelioma, a cancer connected to asbestos exposure, from other carcinomas in the lung.